Paul Ronald Bell
Director/Board Member at BIOTA HOLDINGS LTD.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard James Hill | M | 77 |
Westmead Millennium Institute for Medical Research
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 7 years |
| Ian Gust | M | - |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 23 years |
| Raafat E. F. Fahim | M | 70 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 16 years |
| Patricia Russo | F | 71 | 29 years | |
| Caroline Litchfield | F | 55 | 34 years | |
| Ewoud Jacobus Kulk | M | 77 |
Westmead Millennium Institute for Medical Research
| - |
| Jennifer Hornery | F | - | 16 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Russell H. Plumb | M | 65 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | - |
| Robert P. Luciano | M | - | 23 years | |
| Kenneth Frazier | M | 69 | 30 years | |
| James Fox | M | 73 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 6 years |
| P. Vagelos | M | 94 | 19 years | |
| Joseph Patti | M | 60 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 6 years |
| Damian T. Lismore | M | 64 | 8 years | |
| Geoffrey F. Cox | M | 80 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 12 years |
| Peter J. Azzarello | M | 53 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 years |
| Raymond Gilmartin | M | 82 | 2 years | |
| Jeffery Errington | M | 68 |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | 3 years |
| Thomas Shenk | M | 77 | 11 years | |
| Amanda Lampe | F | - | 2 years | |
| Richard Markham | M | 73 | 20 years | |
| Yasmin Allen | F | 60 | 14 years | |
| Marino Carol | F | - | 8 years | |
| David Gionco | M | 63 | 3 years | |
| Laura Sepp-Lorenzino | M | 63 | 15 years | |
| Donald S. Brooks | M | 88 | - | |
| Andrew Leslie Denver | M | 75 | 16 years | |
| Grant F. Latta | M | - | 5 years | |
| Wendy Yarno | F | 69 | 9 years | |
| Anne Tatlock | F | 84 | - | |
| William Harrison | M | 80 | - | |
| Joseph Romanelli | M | 50 | 19 years | |
| Mark Ziirsen | M | 61 | 5 years | |
| Donal O'Dwyer | M | 71 | 15 years | |
| Ray Jarman | M | - | 16 years | |
| Larry G. Edwards | M | 52 | 15 years | |
| Charles Popper | M | - | 7 years | |
| Carole A. Sable | M | 62 | 12 years | |
| Daniel Bouthillier | M | - | 16 years | |
| Egil Bodd | M | 69 | 11 years | |
| Christine Bunt | F | - | 7 years | |
| Dorothy P. Bowers | F | - | - | |
| Mark Bach | M | 67 | 17 years | |
| Soren Christiansen | M | 68 | 19 years | |
| Ernesto Aycardi | M | 61 | 11 years | |
| David A. Esposito | M | 55 | 13 years | |
| James S. MacDonald | M | - | 17 years | |
| Lisa Escudero | F | 62 | 18 years | |
| Desiree Ralls-Morrison | F | 57 | 8 years | |
| Arthur Santora | M | 73 | 28 years | |
| Jacob Harel | M | 69 | 13 years | |
| Barbara Yanni | F | 69 | 13 years | |
| Sandy Tremps | F | - | 33 years | |
| Glenn Williams | M | - | 10 years | |
| John Renger | M | 55 | 15 years | |
| Mark C. Twyman | M | 63 | 18 years | |
| Eric W. Kimble | M | 58 | 5 years | |
| Jens Renstrup | M | 59 | 8 years | |
| Eric Schadt | M | 59 | 8 years | |
| Joe Pedersen | M | - | 23 years | |
| Hugo Wahnish | M | - | 18 years | |
| Kimberly Murphy | F | 62 | 6 years | |
| Silvana Battaglia | F | 56 | 10 years | |
| Linda Burns | F | - | 1 years | |
| Thomas J. Ouellette | M | - | 16 years | |
| David Arkowitz | M | 62 | 3 years | |
| Philippe Schaison | M | 62 | 7 years | |
| Barry Gumbiner | M | 68 | 6 years | |
| Mark E. McDonough | M | 59 | - | |
| Timothy Proctor | M | 74 | 13 years | |
| Ferdinand E. Massari | M | 64 | 1 years | |
| Nolan Sigal | M | 73 | 10 years | |
| Peter G. Ernster | M | 82 | 26 years | |
| Larry Bossidy | M | 89 | 14 years | |
| Nicolas Barthelemy | M | 58 | 5 years | |
| Joan Wainwright | F | 63 | 6 years | |
| Marcia Avedon | M | 62 | 4 years | |
| Glenn Taylor | M | 72 | 2 years | |
| Paul Howes | M | 69 | 5 years | |
| Elizabeth Hamilton Seabury Wyatt | M | 76 | 20 years | |
| Heidi Miller | M | 70 | 4 years | |
| Samuel O. Thier | M | 86 | 16 years | |
| Gary T. Shearman | M | - | 5 years | |
| Jean-Michael Halfon | M | 72 | 2 years | |
| Gerald J. Gallivan | M | - | - | |
| Ian M. Miller | M | - | 11 years | |
| Michael R. Goldberg | M | - | 17 years | |
| Michael Atieh | M | 70 | 19 years | |
| Frank Verwiel | M | 62 | 4 years | |
| Gregory S. Patrick | M | 72 | 14 years | |
| Ben Shapiro | M | 84 | 13 years | |
| Abraham E. Cohen | M | 86 | 10 years | |
| Alan Nies | M | 86 | 10 years | |
| Jeffrey A. Peris | M | 77 | 25 years | |
| Vijay Samant | M | 77 | 23 years | |
| Margaret McGlynn | F | 64 | 11 years | |
| R. Gordon Douglas | M | 89 | 8 years | |
| Jerome C. Keller | M | 81 | 7 years | |
| Michael M. Tarnow | M | 79 | 22 years | |
| Sean Dobson | M | - | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 90 | 90.00% |
| Australia | 16 | 16.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Paul Ronald Bell
- Personal Network
